Sakharnyy diabet i gormonal'naya enterologiya: put' v prekrasnoe daleko?
https://doi.org/10.14341/2072-0351-5633
Abstract
The gastrointestinal tract produces hormones that influence glucose-induced pancreatic insulin secretion. One of them is glucagon-like peptide 1.Its synthetic analog, liraglutide, has properties that promote metabolic control in patients with type 2 diabetes mellitus and have beneficial effecton the risk factors of cardiovascular complications.
References
1. Bayliss W.M., Starling E.H. The mechanism of pancreatic secretion // J. Physiol. - 1902. - № 28. - Р. 325-353.
2. Solcia E., Capella C., Fiocca R., Sessa F., La Rosa S., Rindi G. Disorders of the endocrine system / In: Ming S.C., Goldman H. (eds). Pathology of the gastrointestinal tract. Saunders. Philadelphia. - 1980. - Р. 240-263.
3. Solcia E., Polak J.M., Pearse A.G.E., Forssmann W.G. Larsson L.I., et al. Lausanne 1977 classification of gastroenteropancreatic endocrine cells / In: gut Hormones, edited by S.R. Bloom, Churchill Livingstone. Edinburgh. - 1978. - Р. 40-48.
4. Rindi G., Capella C., Solcia E. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors // J. Mol. Med. - 1998. - № 76. - Р. 413-420.
5. Feyrter F. Uber diffuse endocrine eitheliale organe / J.A. Barth. - Leipzig. - 1938. - Р. 6-17.
6. Pearse A.G.E., Polak GM. Bifunctional reagents as vapour - and liquid - phase fixatives for immunohistochemistry // Histochem. J. - 1975. - № 7. - Р. 176-186.
7. Rachman J., Barrow B.A., Levy J.C. and Turner R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon- like peptide-1 (GLP-1) in subjects with NIDDM // Diabetologia. - 1997. - № 40. - Р. 205-211.
8. Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., Zdravkovic M., Düring M., Matthews D.R.. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study // Diabetes Care. - 2009. - № 32. - Р. 84-90.
9. Knudsen LB., Nielsen PF., Huusfeldt PO., Johansen NL., Madsen K, Freddy Z. Pedersen, Henning Thøgersen, Michael Wilken, and Henrik Agersø. Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration // J. Med. Chem. - 2000. - № 43. - Р. 1664-1669.
10. Marre M., Shaw J., Brändle M., Bebakar W.M.W., Kamaruddin N.A., Strand J., Zdravkovic M., Le Thi T.D., Colagiuri S. Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) // Diabetic Medicine. - 2009. - № 26. - Р. 268-278.
11. Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., Hale P.M., Zdravkovic M., Bode B., for the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double- blind, parallel-treatment trial // Lancet. - 2009. - № 373. - Р. 481.
12. Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial // Diabetologia. - 52. - Р. 2046-2055.
13. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., Hale P.M., Zdravkovic M., Blonde L., and the LEAD-4 Study Investigators // Diabetes Care. - 2009. - № 32. - Р. 1224-1230.
14. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study // Lancet. - 2002. - № 359. - Р. 824-830.
15. Gutzwiller J.-P., Tschopp S., Bock A., Zehnder C.E., Huber A.R., Kreyenbuehl M., Gutmann H., Drewe J., Henzen C., Goeke B., Beglinger C. Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men // J. Clin. Endocrinol. Metab. - 2004. - № 89. - Р. 3055-3061.
16. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon- Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure // J. Cardiac. Failure. - 2006. - № 12. - Р. 694-699.
17. Nyström T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahrén B., Sjöholm Å. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease // Am. J. Phisiol. Endocrinol Metab. - 2004. - № 287. - Р. E1209-1215.
18. Jendle J., Nauck M. A., Matthews D. R., Frid A., Hermansen K., Düring M., Zdravkovic M., Strauss B. J. and Garber A. J., on behalf of the LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue // Diabetes Obes. Metab. - 2009. - № 11. - Р. 1163-1172.
19. Plutzky L. et al. // Eur Heart J. - 2009. - № 30(Suppl.1). - Р. 917.
20. Plutzky J., Poulter N.R., Falahati A., Toft A.D., Davidson M.H. Abstract 818: Plasminogen Activator Inhibitor-1 is Reduced by the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide When Used in the Treatment of Type 2 Diabetes // Circulation. - 2009. - № 120. - Р. S397.
Review
For citations:
Aleksandrov A.A. Sakharnyy diabet i gormonal'naya enterologiya: put' v prekrasnoe daleko? Diabetes mellitus. 2011;14(2):41-48. (In Russ.) https://doi.org/10.14341/2072-0351-5633
Views:
4180
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
